<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34063031</PMID><DateCompleted><Year>2021</Year><Month>09</Month><Day>22</Day></DateCompleted><DateRevised><Year>2021</Year><Month>09</Month><Day>22</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2218-273X</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>5</Issue><PubDate><Year>2021</Year><Month>May</Month><Day>05</Day></PubDate></JournalIssue><Title>Biomolecules</Title><ISOAbbreviation>Biomolecules</ISOAbbreviation></Journal><ArticleTitle>Some CSF Kynurenine Pathway Intermediates Associated with Disease Evolution in Amyotrophic Lateral Sclerosis.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">691</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/biom11050691</ELocationID><Abstract><AbstractText>The aim of this study was to evaluate the kynurenine pathway (KP) and amino acids profile, using mass spectrometry, in the cerebrospinal fluid (CSF) of 42 amyotrophic lateral sclerosis (ALS) patients at the diagnosis and 40 controls to detect early disorders of these pathways. Diagnostic and predictive ability (based on weight loss, forced vital capacity, ALS Functional Rating Scale-Revised evolution over 12 months, and survival time) of these metabolites were evaluated using univariate followed by supervised multivariate analysis. The multivariate model between ALS and controls was not significant but highlighted some KP metabolites (kynurenine (KYN), kynurenic acid (KYNA), 3-Hydroxynurenine (3-HK)/KYNA ratio), and amino acids (Lysine, asparagine) as involved in the discrimination between groups (accuracy 62%). It revealed a probable KP impairment toward neurotoxicity in ALS patients and in bulbar forms. Regarding the prognostic effect of metabolites, 12 were commonly discriminant for at least 3 of 4 disease evolution criteria. This investigation was crucial as it did not show significant changes in CSF concentrations of amino acids and KP intermediates in early ALS evolution. However, trends of KP modifications suggest further exploration. The unclear kinetics of neuroinflammation linked to KP support the interest in exploring these pathways during disease evolution through a longitudinal strategy.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Alarcan</LastName><ForeName>Hugo</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0001-8707-1722</Identifier><AffiliationInfo><Affiliation>Laboratoire de Biochimie et Biologie Mol&#xe9;culaire, CHRU Bretonneau, 2 Boulevard Tonnell&#xe9;, 37000 Tours, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chaumond</LastName><ForeName>Romane</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Laboratoire de Biochimie et Biologie Mol&#xe9;culaire, CHRU Bretonneau, 2 Boulevard Tonnell&#xe9;, 37000 Tours, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Emond</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-5324-2164</Identifier><AffiliationInfo><Affiliation>UMR 1253 iBrain, Universit&#xe9; de Tours, Inserm, 10 Boulevard Tonnell&#xe9;, 37000 Tours, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratoire de M&#xe9;decine Nucl&#xe9;aire In Vitro, CHRU Bretonneau, 2 Boulevard Tonnell&#xe9;, 37000 Tours, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benz-De Bretagne</LastName><ForeName>Isabelle</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Laboratoire de Biochimie et Biologie Mol&#xe9;culaire, CHRU Bretonneau, 2 Boulevard Tonnell&#xe9;, 37000 Tours, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lef&#xe8;vre</LastName><ForeName>Antoine</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>UMR 1253 iBrain, Universit&#xe9; de Tours, Inserm, 10 Boulevard Tonnell&#xe9;, 37000 Tours, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bakkouche</LastName><ForeName>Salah-Eddine</ForeName><Initials>SE</Initials><AffiliationInfo><Affiliation>Service de Neurologie, CHRU Bretonneau, 2 Boulevard Tonnell&#xe9;, 37000 Tours, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Veyrat-Durebex</LastName><ForeName>Charlotte</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0003-4512-2303</Identifier><AffiliationInfo><Affiliation>Laboratoire de Biochimie et Biologie Mol&#xe9;culaire, CHRU Bretonneau, 2 Boulevard Tonnell&#xe9;, 37000 Tours, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UMR 1253 iBrain, Universit&#xe9; de Tours, Inserm, 10 Boulevard Tonnell&#xe9;, 37000 Tours, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vourc'h</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Laboratoire de Biochimie et Biologie Mol&#xe9;culaire, CHRU Bretonneau, 2 Boulevard Tonnell&#xe9;, 37000 Tours, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UMR 1253 iBrain, Universit&#xe9; de Tours, Inserm, 10 Boulevard Tonnell&#xe9;, 37000 Tours, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andres</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Laboratoire de Biochimie et Biologie Mol&#xe9;culaire, CHRU Bretonneau, 2 Boulevard Tonnell&#xe9;, 37000 Tours, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UMR 1253 iBrain, Universit&#xe9; de Tours, Inserm, 10 Boulevard Tonnell&#xe9;, 37000 Tours, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Corcia</LastName><ForeName>Philippe</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>UMR 1253 iBrain, Universit&#xe9; de Tours, Inserm, 10 Boulevard Tonnell&#xe9;, 37000 Tours, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Service de Neurologie, CHRU Bretonneau, 2 Boulevard Tonnell&#xe9;, 37000 Tours, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blasco</LastName><ForeName>H&#xe9;l&#xe8;ne</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Laboratoire de Biochimie et Biologie Mol&#xe9;culaire, CHRU Bretonneau, 2 Boulevard Tonnell&#xe9;, 37000 Tours, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UMR 1253 iBrain, Universit&#xe9; de Tours, Inserm, 10 Boulevard Tonnell&#xe9;, 37000 Tours, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>05</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Biomolecules</MedlineTA><NlmUniqueID>101596414</NlmUniqueID><ISSNLinking>2218-273X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000596">Amino Acids</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>343-65-7</RegistryNumber><NameOfSubstance UI="D007737">Kynurenine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000596" MajorTopicYN="N">Amino Acids</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007737" MajorTopicYN="N">Kynurenine</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013058" MajorTopicYN="N">Mass Spectrometry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014797" MajorTopicYN="N">Vital Capacity</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">PLS-DA</Keyword><Keyword MajorTopicYN="N">amino acids</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">cerebrospinal fluid</Keyword><Keyword MajorTopicYN="N">kynurenine pathway</Keyword><Keyword MajorTopicYN="N">tryptophan</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>4</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>4</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>5</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>6</Month><Day>2</Day><Hour>1</Hour><Minute>5</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>6</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>9</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34063031</ArticleId><ArticleId IdType="pmc">PMC8147980</ArticleId><ArticleId IdType="doi">10.3390/biom11050691</ArticleId><ArticleId IdType="pii">biom11050691</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Brown R.H., Al-Chalabi A. Amyotrophic Lateral Sclerosis. N. Engl. J. Med. 2017;377:162&#x2013;172. doi: 10.1056/NEJMra1603471.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1603471</ArticleId><ArticleId IdType="pubmed">28700839</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardiman O., Al-Chalabi A., Chio A., Corr E.M., Logroscino G., Robberecht W., Shaw P.J., Simmons Z., van den Berg L.H. Amyotrophic Lateral Sclerosis. Nat. Rev. Dis. Primers. 2017;3:17071. doi: 10.1038/nrdp.2017.71.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrdp.2017.71</ArticleId><ArticleId IdType="pubmed">28980624</ArticleId></ArticleIdList></Reference><Reference><Citation>Dupuis L., Pradat P.-F., Ludolph A.C., Loeffler J.-P. Energy Metabolism in Amyotrophic Lateral Sclerosis. Lancet Neurol. 2011;10:75&#x2013;82. doi: 10.1016/S1474-4422(10)70224-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(10)70224-6</ArticleId><ArticleId IdType="pubmed">21035400</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J.-M., Tan V., Lovejoy D., Braidy N., Rowe D.B., Brew B.J., Guillemin G.J. Involvement of Quinolinic Acid in the Neuropathogenesis of Amyotrophic Lateral Sclerosis. Neuropharmacology. 2017;112:346&#x2013;364. doi: 10.1016/j.neuropharm.2016.05.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropharm.2016.05.011</ArticleId><ArticleId IdType="pubmed">27265569</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan V.X., Guillemin G.J. Kynurenine Pathway Metabolites as Biomarkers for Amyotrophic Lateral Sclerosis. Front. Neurosci. 2019;13:1013. doi: 10.3389/fnins.2019.01013.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2019.01013</ArticleId><ArticleId IdType="pmc">PMC6764462</ArticleId><ArticleId IdType="pubmed">31616242</ArticleId></ArticleIdList></Reference><Reference><Citation>T&#xf6;r&#xf6;k N., Tanaka M., V&#xe9;csei L. Searching for Peripheral Biomarkers in Neurodegenerative Diseases: The Tryptophan-Kynurenine Metabolic Pathway. Int. J. Mol. Sci. 2020;21:9338. doi: 10.3390/ijms21249338.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21249338</ArticleId><ArticleId IdType="pmc">PMC7762583</ArticleId><ArticleId IdType="pubmed">33302404</ArticleId></ArticleIdList></Reference><Reference><Citation>Muneer A. Kynurenine Pathway of Tryptophan Metabolism in Neuropsychiatric Disorders: Pathophysiologic and Therapeutic Considerations. Clin. Psychopharmacol. Neurosci. 2020;18:507&#x2013;526. doi: 10.9758/cpn.2020.18.4.507.</Citation><ArticleIdList><ArticleId IdType="doi">10.9758/cpn.2020.18.4.507</ArticleId><ArticleId IdType="pmc">PMC7609208</ArticleId><ArticleId IdType="pubmed">33124585</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X., Zhang Z.-H., Zabed H.M., Yun J., Zhang G., Qi X. An Insight into the Roles of Dietary Tryptophan and Its Metabolites in Intestinal Inflammation and Inflammatory Bowel Disease. Mol. Nutr. Food Res. 2020:e2000461. doi: 10.1002/mnfr.202000461.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mnfr.202000461</ArticleId><ArticleId IdType="pubmed">33216452</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka M., Toldi J., V&#xe9;csei L. Exploring the Etiological Links behind Neurodegenerative Diseases: Inflammatory Cytokines and Bioactive Kynurenines. Int. J. Mol. Sci. 2020;21:2431. doi: 10.3390/ijms21072431.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21072431</ArticleId><ArticleId IdType="pmc">PMC7177899</ArticleId><ArticleId IdType="pubmed">32244523</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y., Stankovic R., Cullen K.M., Meininger V., Garner B., Coggan S., Grant R., Brew B.J., Guillemin G.J. The Kynurenine Pathway and Inflammation in Amyotrophic Lateral Sclerosis. Neurotox. Res. 2010;18:132&#x2013;142. doi: 10.1007/s12640-009-9129-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12640-009-9129-7</ArticleId><ArticleId IdType="pubmed">19921535</ArticleId></ArticleIdList></Reference><Reference><Citation>I&#x142;zecka J., Kocki T., Stelmasiak Z., Turski W.A. Endogenous Protectant Kynurenic Acid in Amyotrophic Lateral Sclerosis. Acta Neurol. Scand. 2003;107:412&#x2013;418. doi: 10.1034/j.1600-0404.2003.00076.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1034/j.1600-0404.2003.00076.x</ArticleId><ArticleId IdType="pubmed">12757473</ArticleId></ArticleIdList></Reference><Reference><Citation>Janssens J., Vermeiren Y., van Faassen M., van der Ley C., Kema I.P., De Deyn P.P. Monoaminergic and Kynurenergic Characterization of Frontotemporal Dementia and Amyotrophic Lateral Sclerosis in Cerebrospinal Fluid and Serum. Neurochem. Res. 2020;45:1191&#x2013;1201. doi: 10.1007/s11064-020-03002-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11064-020-03002-5</ArticleId><ArticleId IdType="pmc">PMC7162843</ArticleId><ArticleId IdType="pubmed">32130630</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonz&#xe1;lez-S&#xe1;nchez M., Jim&#xe9;nez J., Narv&#xe1;ez A., Antequera D., Llamas-Velasco S., Mart&#xed;n A.H.-S., Arjona J.A.M., de Munain A.L., Bisa A.L., Marco M.-P., et al. Kynurenic Acid Levels Are Increased in the CSF of Alzheimer&#x2019;s Disease Patients. Biomolecules. 2020;10:571. doi: 10.3390/biom10040571.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biom10040571</ArticleId><ArticleId IdType="pmc">PMC7226436</ArticleId><ArticleId IdType="pubmed">32276479</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks B.R., Miller R.G., Swash M., Munsat T.L. World Federation of Neurology Research Group on Motor Neuron Diseases El Escorial Revisited: Revised Criteria for the Diagnosis of Amyotrophic Lateral Sclerosis. Amyotroph. Lateral Scler. Motor Neuron Disord. 2000;1:293&#x2013;299. doi: 10.1080/146608200300079536.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/146608200300079536</ArticleId><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>Birner A., Platzer M., Bengesser S.A., Dalkner N., Fellendorf F.T., Queissner R., Pilz R., Rauch P., Maget A., Hamm C., et al. Increased Breakdown of Kynurenine towards Its Neurotoxic Branch in Bipolar Disorder. PLoS ONE. 2017;12:e0172699. doi: 10.1371/journal.pone.0172699.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0172699</ArticleId><ArticleId IdType="pmc">PMC5328271</ArticleId><ArticleId IdType="pubmed">28241062</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothstein J.D., Tsai G., Kuncl R.W., Clawson L., Cornblath D.R., Drachman D.B., Pestronk A., Stauch B.L., Coyle J.T. Abnormal Excitatory Amino Acid Metabolism in Amyotrophic Lateral Sclerosis. Ann. Neurol. 1990;28:18&#x2013;25. doi: 10.1002/ana.410280106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410280106</ArticleId><ArticleId IdType="pubmed">2375630</ArticleId></ArticleIdList></Reference><Reference><Citation>Perry T.L., Krieger C., Hansen S., Eisen A. Amyotrophic Lateral Sclerosis: Amino Acid Levels in Plasma and Cerebrospinal Fluid. Ann. Neurol. 1990;28:12&#x2013;17. doi: 10.1002/ana.410280105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410280105</ArticleId><ArticleId IdType="pubmed">2375629</ArticleId></ArticleIdList></Reference><Reference><Citation>Blin O., Samuel D., Nieoullon A., Serratice G. Changes in CSF Amino Acid Concentrations during the Evolution of Amyotrophic Lateral Sclerosis. J. Neurol. Neurosurg. Psychiatry. 1994;57:119&#x2013;120. doi: 10.1136/jnnp.57.1.119-a.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.57.1.119-a</ArticleId><ArticleId IdType="pmc">PMC485053</ArticleId><ArticleId IdType="pubmed">8301293</ArticleId></ArticleIdList></Reference><Reference><Citation>Meier D.H., Schott K.J. Free Amino Acid Pattern of Cerebrospinal Fluid in Amyotrophic Lateral Sclerosis. Acta Neurol. Scand. 1988;77:50&#x2013;53. doi: 10.1111/j.1600-0404.1988.tb06973.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-0404.1988.tb06973.x</ArticleId><ArticleId IdType="pubmed">3128052</ArticleId></ArticleIdList></Reference><Reference><Citation>Valentino F., Bivona G., Butera D., Paladino P., Fazzari M., Piccoli T., Ciaccio M., La Bella V. Elevated Cerebrospinal Fluid and Plasma Homocysteine Levels in ALS. Eur. J. Neurol. 2010;17:84&#x2013;89. doi: 10.1111/j.1468-1331.2009.02752.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1468-1331.2009.02752.x</ArticleId><ArticleId IdType="pubmed">19659753</ArticleId></ArticleIdList></Reference><Reference><Citation>Blasco H., Corcia P., Moreau C., Veau S., Fournier C., Vourc&#x2019;h P., Emond P., Gordon P., Pradat P.-F., Praline J., et al. 1H-NMR-Based Metabolomic Profiling of CSF in Early Amyotrophic Lateral Sclerosis. PLoS ONE. 2010;5:e13223. doi: 10.1371/annotation/2c2f8fce-a5be-40a3-af8f-48f119b2c593.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/annotation/2c2f8fce-a5be-40a3-af8f-48f119b2c593</ArticleId><ArticleId IdType="pmc">PMC2951909</ArticleId><ArticleId IdType="pubmed">20949041</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu J., Wuolikainen A., Trupp M., Jonsson P., Marklund S.L., Andersen P.M., Forsgren L., &#xd6;hman A. NMR Analysis of the CSF and Plasma Metabolome of Rigorously Matched Amyotrophic Lateral Sclerosis, Parkinson&#x2019;s Disease and Control Subjects. Metabolomics. 2016;12:101. doi: 10.1007/s11306-016-1041-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11306-016-1041-6</ArticleId><ArticleId IdType="pubmed">26883206</ArticleId></ArticleIdList></Reference><Reference><Citation>Wuolikainen A., Jonsson P., Ahnlund M., Antti H., Marklund S.L., Moritz T., Forsgren L., Andersen P.M., Trupp M. Multi-Platform Mass Spectrometry Analysis of the CSF and Plasma Metabolomes of Rigorously Matched Amyotrophic Lateral Sclerosis, Parkinson&#x2019;s Disease and Control Subjects. Mol. Biosyst. 2016;12:1287&#x2013;1298. doi: 10.1039/C5MB00711A.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/C5MB00711A</ArticleId><ArticleId IdType="pubmed">26883206</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruno C., Veyrat-Durebex C., Lumbu Lukuntonda C.H., Andres C.R., Moreau C., Bendavid C., Homedan C., Labarthe F., Tardieu M., Bigot A., et al. Validation of Plasma Amino Acid Profile Using UHPLC-Mass Spectrometer (QDa) as a Screening Method in a Metabolic Disorders Reference Centre: Performance and Accreditation Concerns. Clin. Biochem. 2021 doi: 10.1016/j.clinbiochem.2021.03.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinbiochem.2021.03.004</ArticleId><ArticleId IdType="pubmed">33736999</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng Kee Kwong K.C., Harbham P.K., Selvaraj B.T., Gregory J.M., Pal S., Hardingham G.E., Chandran S., Mehta A.R. 40 Years of CSF Toxicity Studies in ALS: What Have We Learnt About ALS Pathophysiology? Front. Mol. Neurosci. 2021;14:647895. doi: 10.3389/fnmol.2021.647895.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2021.647895</ArticleId><ArticleId IdType="pmc">PMC8012723</ArticleId><ArticleId IdType="pubmed">33815058</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw P.J., Forrest V., Ince P.G., Richardson J.P., Wastell H.J. CSF and Plasma Amino Acid Levels in Motor Neuron Disease: Elevation of CSF Glutamate in a Subset of Patients. Neurodegeneration. 1995;4:209&#x2013;216. doi: 10.1006/neur.1995.0026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/neur.1995.0026</ArticleId><ArticleId IdType="pubmed">7583686</ArticleId></ArticleIdList></Reference><Reference><Citation>Bereman M.S., Kirkwood K.I., Sabaretnam T., Furlong S., Rowe D.B., Guillemin G.J., Mellinger A.L., Muddiman D.C. Metabolite Profiling Reveals Predictive Biomarkers and the Absence of &#x3b2;-Methyl Amino-l-Alanine in Plasma from Individuals Diagnosed with Amyotrophic Lateral Sclerosis. J. Proteome Res. 2020;19:3276&#x2013;3285. doi: 10.1021/acs.jproteome.0c00216.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jproteome.0c00216</ArticleId><ArticleId IdType="pubmed">32418425</ArticleId></ArticleIdList></Reference><Reference><Citation>Thonhoff J.R., Simpson E.P., Appel S.H. Neuroinflammatory Mechanisms in Amyotrophic Lateral Sclerosis Pathogenesis. Curr. Opin. Neurol. 2018;31:635&#x2013;639. doi: 10.1097/WCO.0000000000000599.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WCO.0000000000000599</ArticleId><ArticleId IdType="pubmed">30048339</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyon M.S., Wosiski-Kuhn M., Gillespie R., Caress J., Milligan C. Inflammation, Immunity, and Amyotrophic Lateral Sclerosis: I. Etiology and Pathology. Muscle Nerve. 2019;59:10&#x2013;22. doi: 10.1002/mus.26289.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.26289</ArticleId><ArticleId IdType="pubmed">29979464</ArticleId></ArticleIdList></Reference><Reference><Citation>B&#xe9;land L.-C., Markovinovic A., Jakovac H., De Marchi F., Bilic E., Mazzini L., Kriz J., Munitic I. Immunity in Amyotrophic Lateral Sclerosis: Blurred Lines between Excessive Inflammation and Inefficient Immune Responses. Brain Commun. 2020;2:fcaa124. doi: 10.1093/braincomms/fcaa124.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/braincomms/fcaa124</ArticleId><ArticleId IdType="pmc">PMC7585698</ArticleId><ArticleId IdType="pubmed">33134918</ArticleId></ArticleIdList></Reference><Reference><Citation>Agus A., Planchais J., Sokol H. Gut Microbiota Regulation of Tryptophan Metabolism in Health and Disease. Cell Host Microbe. 2018;23:716&#x2013;724. doi: 10.1016/j.chom.2018.05.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2018.05.003</ArticleId><ArticleId IdType="pubmed">29902437</ArticleId></ArticleIdList></Reference><Reference><Citation>Quigley E.M.M. Microbiota-Brain-Gut Axis and Neurodegenerative Diseases. Curr. Neurol. Neurosci. Rep. 2017;17:94. doi: 10.1007/s11910-017-0802-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11910-017-0802-6</ArticleId><ArticleId IdType="pubmed">29039142</ArticleId></ArticleIdList></Reference><Reference><Citation>Wi&#x119;d&#x142;ocha M., Marcinowicz P., Janoska-Ja&#x17a;dzik M., Szulc A. Gut Microbiota, Kynurenine Pathway and Mental Disorders&#x2014;Review. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2020:110145. doi: 10.1016/j.pnpbp.2020.110145.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pnpbp.2020.110145</ArticleId><ArticleId IdType="pubmed">33203568</ArticleId></ArticleIdList></Reference><Reference><Citation>Kennedy P.J., Cryan J.F., Dinan T.G., Clarke G. Kynurenine Pathway Metabolism and the Microbiota-Gut-Brain Axis. Neuropharmacology. 2017;112:399&#x2013;412. doi: 10.1016/j.neuropharm.2016.07.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropharm.2016.07.002</ArticleId><ArticleId IdType="pubmed">27392632</ArticleId></ArticleIdList></Reference><Reference><Citation>Erber A.C., Cetin H., Berry D., Schernhammer E.S. The Role of Gut Microbiota, Butyrate and Proton Pump Inhibitors in Amyotrophic Lateral Sclerosis: A Systematic Review. Int. J. Neurosci. 2020;130:727&#x2013;735. doi: 10.1080/00207454.2019.1702549.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/00207454.2019.1702549</ArticleId><ArticleId IdType="pubmed">31870202</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>